The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1537
January 1, 2018
View Complete Issue         Table of Contents 2019 
Betrixaban (Bevyxxa) for VTE Prophylaxis in Acute Medical Illness
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Betrixaban (Bevyxxa) for VTE Prophylaxis in Acute Medical Illness
January 1, 2018 (Issue: 1537)
The FDA has approved betrixaban (Bevyxxa – Portola), a once-daily, oral, direct factor Xa inhibitor, for prophylaxis of venous thromboembolism (VTE) in adults hospitalized for an acute medical illness who have moderately or severely restricted...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Betrixaban (Bevyxxa) for VTE Prophylaxis in Acute Medical Illness
Article code: 1537b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.